Related references
Note: Only part of the references are listed.Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Andres Poveda et al.
CANCERS (2022)
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
Sonia Singh et al.
CLINICAL CANCER RESEARCH (2021)
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
Sandro Pignata et al.
ONCOLOGIST (2021)
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
Rebecca Kristeleit et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
Andres Poveda et al.
SCIENTIFIC REPORTS (2021)
Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue Diagnosis and Management of Endometrial Cancer
Angiolo Gadducci et al.
CANCERS (2021)
Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
Dario P. Anobile et al.
CANCERS (2021)
Real-world experience with trabectedin for the treatment of recurrent ovarian cancer
Ignacio Romero et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
Stephanie Gaillard et al.
GYNECOLOGIC ONCOLOGY (2021)
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
P. Pautier et al.
ESMO OPEN (2021)
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Y. Metaxas et al.
ANNALS OF ONCOLOGY (2020)
Enriching cancer pharmacology with drugs of marine origin
Paula C. Jimenez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas
Gregory M. Cote et al.
EUROPEAN JOURNAL OF CANCER (2020)
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
Shaily Arora et al.
CLINICAL CANCER RESEARCH (2020)
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
Carlos Fernandez-Teruel et al.
CLINICAL PHARMACOKINETICS (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer
Antonio Casado et al.
FUTURE ONCOLOGY (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma
Angiolo Gadducci et al.
BRITISH JOURNAL OF CANCER (2018)
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
Giovanni Grignani et al.
LANCET ONCOLOGY (2018)
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors
Luis Paz-Ares et al.
INVESTIGATIONAL NEW DRUGS (2017)
Trabectedin mechanism of action and platinum resistance: molecular rationale
Isabelle Ray-Coquard
FUTURE ONCOLOGY (2017)
Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer
Jean-Philippe Adam et al.
GYNECOLOGIC ONCOLOGY (2017)
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2017)
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA singleand double-strand breaks, on a weekly x 2 every-3-week schedule
Antonio Jimeno et al.
INVESTIGATIONAL NEW DRUGS (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Ymera Pignochino et al.
MOLECULAR CANCER (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen
Amy Barone et al.
CLINICAL CANCER RESEARCH (2017)
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein
E. Erba et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
E. Calvo et al.
ANNALS OF ONCOLOGY (2017)
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
Cristina Belgiovine et al.
BRITISH JOURNAL OF CANCER (2017)
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
A. Poveda et al.
ANNALS OF ONCOLOGY (2017)
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
D. Lorusso et al.
ANNALS OF ONCOLOGY (2016)
Tumor-associated macrophages and anti-tumor therapies: complex links
Cristina Belgiovine et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Gema Santamaria Nunez et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment
Manuela Liguori et al.
ONCOTARGET (2016)
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
Michelle Lima et al.
ONCOTARGET (2016)
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
Ryoko Takahashi et al.
PLOS ONE (2016)
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study
B. J. Monk et al.
ANNALS OF ONCOLOGY (2015)
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
B. Colmegna et al.
BRITISH JOURNAL OF CANCER (2015)
Challenges in SN38 drug delivery: current success and future directions
Srinath Palakurthi
EXPERT OPINION ON DRUG DELIVERY (2015)
Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer
Shaheenah Dawood et al.
FUTURE ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The interaction of anticancer therapies with tumor-associated macrophages
Alberto Mantovani et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
Zhiqiang Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
J. Balmana et al.
ANNALS OF ONCOLOGY (2014)
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Barbara Lupo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
M. D'Incalci et al.
BRITISH JOURNAL OF CANCER (2014)
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G. Del Conte et al.
BRITISH JOURNAL OF CANCER (2014)
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
Maria Elena Elez et al.
CLINICAL CANCER RESEARCH (2014)
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
X. Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung-Min Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Giovanni Germano et al.
CANCER CELL (2013)
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
Michela Romano et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
Jose Maria del Campo et al.
MEDICAL ONCOLOGY (2013)
Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
August Vidal et al.
CLINICAL CANCER RESEARCH (2012)
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial
A. Poveda et al.
ANNALS OF ONCOLOGY (2011)
The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2011)
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2011)
Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers
Roberta Sanfilippo et al.
GYNECOLOGIC ONCOLOGY (2011)
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
J. F. M. Leal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas Report on Five Patients and a Review of the Literature
Frederic Amant et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
C. N. Krasner et al.
BRITISH JOURNAL OF CANCER (2007)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Tumor models for efficacy determination
Beverly A. Teicher
MOLECULAR CANCER THERAPEUTICS (2006)
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
F. Grosso et al.
EUROPEAN JOURNAL OF CANCER (2006)
Rho GTPases in cell biology
S Etienne-Manneville et al.
NATURE (2002)
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
G Damia et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
